RxDoctor Payments Data

Gary Leach, MD

Urology · Los Angeles, CANPI 1225062797

Payments from drug & device makers

$131,786in general payments, 2019–2025

Across 574 payments — averaging $229.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$110K
  • Astellas Pharma US Inc$11K
  • AbbVie$5K
  • Coloplast$755
  • Teleflex LLC$463
  • Boston Scientific$437
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$2,5002%
  • Speaking & faculty fees$110,92586%
  • Travel & lodging$5190%
  • Food & beverage$14,82511%
  • Education$4410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)276$110,472
Astellas Pharma US Inc35$10,724
AbbVie(2 entities)92$4,676
Coloplast23$755
Teleflex LLC10$463
Boston Scientific6$437
Urogen Pharma, Inc.2$366
Myovant Sciences Inc.14$365
Dendreon Pharmaceuticals LLC3$358
Axonics, Inc.5$350
BD4$334
Pfizer13$280
Johnson & Johnson(2 entities)14$277
Rochester Medical Corporation15$170
Sumitomo Pharma America, Inc.6$154
Laborie Medical Technologies Corp.2$135
Calyxo, Inc.1$130
C. R. Bard, Inc. & Subsidiaries5$129
Bayer6$127
Telix Pharmaceuticals4$118
Dornier Medtech America, Inc1$102
Urovant Sciences Inc4$92
Profound Medical Corp.1$88
Ferring Pharmaceuticals Inc.5$85
Merck3$75
Blue Earth Diagnostics3$73
Neotract Inc.3$66
Immunitybio, Inc.3$65
ABC Home Medical Supply, Inc.3$54
Astellas Pharma Global Development1$44
Contura, Inc.1$42
Myriad Genetic Laboratories, Inc.2$32
Hollister Incorporated2$29
180 Medical, Inc.1$28
Verity Pharmaceuticals Inc.1$19
Progenics Pharmaceuticals, Inc.1$19
Dentsply IH Inc.1$18
AstraZeneca1$16
Antares Pharma, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,786 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$628,400
Medicare patients
655
Services billed
36,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron393$323,045
MyrbetriqMirabegron50$34,349
Silodosin60$4,042
Tamsulosin Hcl136$1,864
Tolterodine Tartrate ErTolterodine Tartrate11$1,359
NitrofurantoinNitrofurantoin Macrocrystal47$1,122
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$877
Dutasteride37$671
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim70$322
Ciprofloxacin Hcl63$282
Finasteride28$256
CefuroximeCefuroxime Axetil18$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$154$323,045393 claims
Astellas Pharma US IncMyrbetriq$10,724$34,34950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.

Other urology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →